SciBrunch Therapeutics and Merck & Co., Inc. (MSD; NYSE: MRK) jointly announced an exclusive global licensing agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor. Under the closed transaction, SciBrunch receives an upfront payment of USD 400 million and is eligible for milestone payments across multiple indications, bringing the potential total deal value to up to USD 2.13 billion — one of the largest preclinical licensing deals struck by a Chinese biotech and a bold move by Merck into the red-hot KRAS-targeted oncology arena.
Deal Snapshot
| Item | Detail |
|---|---|
| Licensee | Merck & Co., Inc. (MSD; NYSE: MRK) |
| Licensor | SciBrunch Therapeutics (Shanghai, China) |
| Asset | SPR2015 — investigational preclinical oral KRAS G12D (ON) inhibitor (molecular glue modality) |
| Rights Granted | Exclusive global rights to develop, manufacture, and commercialize |
| Upfront Payment | USD 400 million |
| Milestones | Development, commercialization, and other activities across multiple indications |
| Total Potential Value | Up to USD 2.13 billion (including upfront) |
| Transaction Status | Closed |
| Announcement Date | 28 Sep 2026 |
Drug Profile & Mechanism of Action
- Modality: A novel, highly potent, and highly selective molecular glue KRAS G12D (ON) inhibitor — a small molecule that stabilizes a protein–protein interaction to degrade or disable the mutant KRAS G12D protein in its active (ON) state.
- Target Rationale: KRAS G12D is the most prevalent KRAS mutation across pancreatic, colorectal, and gastric cancers — historically “undruggable” targets now yielding to a new wave of allele-selective inhibitors.
- Potency: Demonstrated nanomolar-level antiproliferative activity across multiple KRAS G12D-mutated tumor cell lines.
- Selectivity: Maintains favorable selectivity over wild-type KRAS — a critical safety attribute, since wild-type KRAS inhibition drives on-target toxicities that have constrained earlier programs.
- Administration: Oral, positioning SPR2015 for outpatient chronic dosing and combination regimens.
Preclinical Evidence
| Evidence Type | Findings |
|---|---|
| In Vitro | Nanomolar-level antiproliferative activity across multiple KRAS G12D-mutated tumor cell lines; favorable selectivity over wild-type KRAS |
| In Vivo | As monotherapy, significant antitumor activity across various cell line-derived and patient-derived xenograft (CDX/PDX) models |
| Disclosure Venue | 2026 American Association for Cancer Research (AACR) Annual Meeting |
| Clinical Data | None yet — preclinical asset; first-in-human timing not disclosed |
At the 2026 AACR Annual Meeting, SciBrunch presented preclinical results showing SPR2015 monotherapy delivered significant antitumor activity across a range of CDX and PDX models — patient-derived xenografts being among the most translational preclinical systems available, supporting progression toward clinical development.
Market Impact & Outlook
- Merck’s Oncology Pipeline Depth: Acquiring global rights to a differentiated oral KRAS G12D molecular glue diversifies Merck’s oncology portfolio beyond Keytruda-centric immuno-oncology and positions the company in the KRAS G12D race alongside Amgen, Mirati/BMS, Jacobio, and others pursuing the same allele.
- Preclinical Premium: A USD 400 million upfront for a preclinical-stage molecule reflects both the scarcity of potent, selective G12D assets and pharma’s willingness to pay platform-level prices for next-generation KRAS modalities.
- SciBrunch Validation: The transaction marks a landmark outbound licensing win for the Shanghai-based biotech, monetizing its molecular glue discovery engine while retaining no territorial carve-out — full global rights transfer to MSD.
- Indication Optionality: KRAS G12D spans pancreatic ductal adenocarcinoma, colorectal, and gastric cancers — some of the highest-need, highest-mortality solid tumors — giving the deal “multiple indications” milestone breadth.
- Execution Risk: SPR2015 remains preclinical; first-in-human studies, dose-limiting toxicities, and head-to-head differentiation versus competing G12D inhibitors are yet to be established. Development timelines were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development, regulatory milestones, and commercial expectations for SPR2015 under the SciBrunch–Merck licensing agreement. Actual results may differ materially due to risks including preclinical-to-clinical translation, safety and tolerability findings in humans, competitive dynamics in KRAS-targeted therapy, and the achievement of milestone-triggering events.-Fineline Info & Tech
